[Study on the transfer of cefminox into female genital organs].
One gram of cefminox (CMNX, MT-141) was injected intravenously to a total of 29 patients prior to abdominal total hysterectomy and drug levels in the uterine and adnexal tissues were bioassayed. Serum samples and uterine tissues were taken at 0.25, 0.5, 1, 2, 4 or 6 hours after the administration, when bilateral uterine arteries were clamped. As to serum levels no difference has seen between cubital venous serum and uterine arterial serum, the half-lives being 2.32 hours and 2.22 hours, respectively. The peak level was 66.7 micrograms/ml for both. The drug level in tissues reached its peak at 15 minutes in the myometrium and cervix uteri, at 30 minutes in the endometrium, portio vaginalis and oviduct and at 1 hour in the ovary. The mean peak level was the highest for the oviduct (55.3 micrograms/g), followed by the portio vaginalis (47.7 micrograms/g), the cervix uteri (46.2 micrograms/g), the myometrium (42.8 micrograms/g), the ovary (37.3 micrograms/g) and the endometrium (34.2 micrograms/g) in this order. After reached the highest levels, the tissue levels decreased gradually in the same manner as the serum levels. From these results it was shown that CMNX is well transferred into various female genital tissues to achieve concentrations higher than MICs for organisms isolated clinically with high incidences in the field of gynecology and obstetrics. It was assumed from these results that CMNX is clinically useful enough in the treatment of genital organ infections.
D000328:Adult; D002513:Cephamycins / Q000097:blood / Q000378:metabolism*; D005260:Female; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D007889:Leiomyoma / Q000378:metabolism / Q000601:surgery; D008875:Middle Aged; D010053:Ovary / Q000378:metabolism; D014594:Uterine Neoplasms / Q000378:metabolism / Q000601:surgery; D014599:Uterus / Q000378:metabolism
D002513:Cephamycins; C046079:cefminox